Agency Future Formula review: what the current Night Renew Rx record says

The Agency product page identifies Night Renew Rx, shows $130 and describes 24 g as a 60-day supply. Its pricing article, dated August 28, 2026, expressly says it was formerly Future Formula. These are stronger identifiers than an old review title or a search result that retains the previous name.

A published mass is useful, but it is still an offer record rather than an inspected container. The options comparison keeps that distinction beside the named formula. We have not verified that a particular prescription, package or initial shipment has the same specifications or confirmed how any reader would be directed to use it.

The product description lists possible ingredients including tretinoin, dexpanthenol, estriol, tranexamic acid, azelaic acid, glycerin and niacinamide. The ingredient article says up to four actives may be included, selected by the medical provider. The product page also states that not all formulas contain tretinoin.

This means the name cannot establish a complete recipe. The safety record identifies estriol as an estrogen and discusses additional ingredient-specific considerations. Its presence in the possible menu should not be flattened into a generic nonhormonal skincare description. Nor does an option list establish that estriol is included in any particular prescription. Our combination guide explains why ingredients need their own verified fields.

Agency publishes base ingredients, but the qualification about propylene glycol is phrased differently across current records. The product page and August 26 ingredient article say every Night Renew formula includes it. The August 22 safety page specifies its inclusion in formulas with dexpanthenol or niacinamide. The latter does not explicitly establish a propylene-glycol-free option.

The careful conclusion is to confirm the actual complete formula rather than infer an exclusion from the narrower sentence. The product and ingredient pages additionally identify BHT in tretinoin-containing formulas. Our vehicle discussion treats these qualifications as product-identification questions, not a method for predicting an allergy or selecting a preparation.

The pricing page states $130 per subscription order for Night Renew, with free shipping and tax where applicable. Orders are automatically scheduled every 60 days. The same record specifies one consultation credit for each shipment received; credits do not expire, and additional consultations cost $10 each. Those details qualify a general promise of ongoing provider access.

The page also lists discounts when additional prescription products are combined in an order. We do not treat those offers as a clinical reason to combine products or calculate a necessary annual spend. An order containing other items has a different scope. This review does not verify an initial assessment charge, a payment transaction or an individual’s final quote.

Agency’s safety page explicitly calls Night Renew a compounded prescription medicine and says there is no fixed formula. It explains that ingredients and strengths follow clinical assessment. The page’s description of its compounding arrangements is a provider statement, not an independent compliance or pharmacy-quality finding from this publication.

FDA explains the absence of premarket approval for compounded medicines. Product advertising about stronger or gentler options does not establish comparative clinical results for a particular mixture. Similarly, the RENOVA label concerns its own finished preparation. It cannot establish Night Renew’s approval or validate broad skin-longevity language. Our CoreAge review holds the featured product to the same boundary.

The Agency safety information says the prescribed actives will appear on the bottle label and discusses a product-specific beyond-use date. It also explains that formulations can differ among patients and change over time. Those statements make the current supplied record more relevant than a screenshot of a past ingredient selection.

The container guide addresses questions about the actual package and its instructions. We do not assign a storage temperature or a usable life from the advertised 60-day supply. A supply description, a clinical plan and a date printed by a pharmacy serve different purposes, even when they all concern the same container.

Agency provides more current detail than the old Future Formula name conveys: a new product identity, a stated package amount, a variable ingredient menu and a defined consultation-credit model. It also leaves the exact individual formula conditional. Those are the useful findings, rather than a verdict that one strength or added active makes a better cream.

The current terms describe dermatology subscription refills and distinguish them from other services. They do not turn the public product page into an individual prescription. Clinical concerns and unwanted changes require the responsible professional’s assessment; neither a “gentler” claim nor a branded longevity narrative supplies a personal answer.